Hemab Therapeutics, a clinical-stage biotechnology firm growing the primary prophylactic therapeutics for critical, underserved bleeding and thrombotic problems, has introduced the closing of an oversubscribed $135 million Sequence B financing.
Entry Biotechnology led the spherical, with participation from new buyers Deep Observe Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Make investments Fairness, in addition to all present buyers Novo Holdings, RA Capital Administration, and HealthCap.
“Hemab is essentially reimagining the therapy paradigm for underserved bleeding and thrombotic problems. This financing will permit us to progress our medical packages for the primary prophylactic therapies for Glanzmann Thrombasthenia and von Willebrand Illness, delivering useful cures for sufferers in want,” mentioned Benny Sorensen, CEO and president of Hemab.
“We’re grateful for this sturdy syndicate of buyers who assist our strategy of leveraging validated superior applied sciences and deep insights into the biology of clotting to beat many years of scientific stagnation.”
Creating 5 belongings
The financing will assist Hemab’s scientific and company progress plans via 2025, together with completion of an ongoing part 1/2 medical examine of lead candidate HMB-001 in Glanzmann thrombasthenia, initiation of pivotal research, begin and completion of part 1/2 medical analysis for HMB-VWF in von Willebrand illness, and future pipeline evolution in accordance with the corporate’s Hemab 1-2-5 strategic steering, which targets the event of 5 medical belongings by 2025.
“Sturdy investor confidence—on this case, an upsized spherical and greater than $200 million in demand—is a testomony to the experience of the Hemab staff, their validated scientific strategy, and the chance to convey long-overdue innovation to sufferers residing with extreme bleeding and thrombotic illnesses,” mentioned John Maraganore, chair of Hemab’s board of administrators.
About HMB-001
HMB-001 is bispecific antibody that binds and stabilizes endogenous issue VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets with the opposite arm. This enables for accumulation of FVIIa within the physique, recruitment of FVIIa on to the floor of the activated platelets the place it’s identified to facilitate clotting, and avoidance of clotting exercise within the absence of tissue harm.
HMB-001 was designed to be a first-in-class prophylactic therapy for Glanzmann thrombasthenia with potential for different debilitating uncommon bleeding problems. It entered part 1/2 medical analysis in late 2022, with preliminary knowledge anticipated 2H 2023.
